Jiuzhou Pharmaceutical(SH:603456) Zheng Quan Zhi Xing·2025-08-05 16:10Group 1 - The core viewpoint of the article is that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is using part of the raised funds to increase capital for its project implementation entity, Jiuzhou Pharmaceutical (Taizhou) Co., Ltd., to ensure the smooth progress of its investment projects [1][6][8] Group 2 - The total amount of funds raised through the non-public offering of 65,291,198 shares at a price of 38.29 RMB per share is approximately 2.49 billion RMB, after deducting issuance costs [1][4] - The funds will be allocated to the construction of the innovative drug CDMO production base project (Phase I) and the raw material drug CDMO construction project [2][4] - The capital increase plan involves an investment of 200 million RMB into Jiuzhou Pharmaceutical (Taizhou), raising its registered capital from 175 million RMB to 190 million RMB [5][6] Group 3 - The company has established a special account for the raised funds and signed a regulatory agreement with the sponsor and the bank to ensure proper management and usage of the funds [6][7] - The board of directors and the supervisory board have approved the use of the funds for the capital increase, confirming that it aligns with the interests of the company and its shareholders [7][8] - The sponsor, Huatai United Securities, has verified that the capital increase does not alter the direction of the raised funds and complies with relevant regulations [8]